The company behind the popular weight loss drug Maunzaro has offered a concessional deal to the UK suppliers, expecting consumers to limit the price hike from September.
Earlier this month, Elli Lily announced that the list of drug is keeping the value up to 170%, which could mean the highest dose cost was going from £ 122 to £ 330 per month.
But BBC understands that the highest dose will now be sold to suppliers for £ 247.50.
Pharmacies and other private weight-loss services will add their own mark-ups to consumers, but this means that the price for patients is unlikely to grow as growth as much as fear in the beginning.
Eli Lily originally stated that the price of Munzaro UK had to increase in Europe and America to increase higher prices.
US President Donald Trump had earlier complained about the high cost of drugs in the USCompared to other countries, and if they did not work, threatened the pharmaceutical industry.
The deal does not affect the price paid by NHS, as the service has negotiated its heavy-discounted rate for those receiving drugs on prescription.
Weekly injection works to make you feel full so that you can eat less, and help people lose 20% of your body weight.
Currently, about 1.5 million people are believed to be on weight loss drugs in the UK, of which more than half of which are at silence. To purchase from online services and high street pharmacies, 10 salary in 10 salary for these drugs is estimated.
Elli Lily said: “We are working with private providers on commercial arrangements to maintain strength and hope that patients will be passed when the changes are effective on 1 September.
“We are already looking at the providers responding differently for list price changes, many options are available for eligible patients.”
The price that the consumer pays depends on which service they buy weight loss medicine.
Some provide more lifestyle and dietary support during medication than other people.
The BBC has talked to several services and the price increase for customers can be kept less than 50% for high doses and even lower for low doses.
Olivier Picard of the National Pharmacy Association said: “They will all do to support patients when pharmacies are converted into prices.
“This exemption will reduce some effects of growth, but patients should still guess the price increase from 1 September.
“Pharmacies are working hard to support their patients and find out if there are options to reduce disruption in their treatment program.”
